Atsuko Hirabae
Okayama, 7008558, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment.
Journal: Current oncology (Toronto, Ont.)
Published: April 08, 2026
Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation.
Journal: Molecular cancer therapeutics
Published: January 19, 2025
Chemo-preventive effects and antitumorigenic mechanisms of beer and nonalcoholic beer toward 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) - induced lung tumorigenesis in A/J mice.
Journal: Genes and environment : the official journal of the Japanese Environmental Mutagen Society
Published: April 24, 2023
CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Journal: Translational lung cancer research
Published: February 11, 2023
PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 19, 2022
CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.
Journal: Cancer immunology research
Published: September 07, 2021
A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide.
Journal: International cancer conference journal
Published: January 04, 2021
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.
Journal: Nature communications
Published: November 25, 2020
Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab.
Journal: Acta medica Okayama
Published: October 27, 2020
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Journal: Cancer science
Published: August 28, 2020
Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer.
Journal: In vivo (Athens, Greece)
Published: July 20, 2019
Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Journal: Japanese journal of clinical oncology
Published: January 27, 2019
Showing 1-12 of 12
Last Updated: 09/26/2026